As of September 2025, Neuralink has announced that 12 individuals worldwide have received its neural implants, a notable jump from just seven recipients reported in June 2025. These implants are part of the ongoing N1 brain-computer interface trials aimed at enabling control of digital and physical devices via thought.
Milestone Momentum & Innovation Highlights
- From Seven to Twelve Recipients: The increase highlights a deliberate ramp-up in Neuralink’s clinical efforts — part of broader efforts to demonstrate safety and functionality across more participants.
- Cumulative Use: These users collectively have amassed over 2,000 days and 15,000 hours of real-world use—indicating extensive trial activity and behavioral data.
- UK Expansion on the Horizon: To broaden its clinical footprint, Neuralink is planning trials in the UK in collaboration with University College London Hospitals and Newcastle Hospitals.
Context: Neuralink’s Human Trials
- 2024 Launch: Neuralink began human studies in 2024 after addressing FDA safety concerns that initially delayed approval. Reuters
- Initial Milestones: By early 2025, the first three human implant recipients were already performing tasks such as moving computer cursors and playing video games using only neural signals—powered by enhanced electrode arrays and improved device specifications.
Why It Matters
| Impact Area | Insight |
|---|---|
| Clinical Progress | Reaching 12 implanted individuals validates Neuralink’s accelerated progress in human trials. |
| Data & Usage | Extensive usage hours help refine the technology for safety and efficacy—crucial for future FDA approval. |
| Global Reach | Launching clinical trials in the UK marks Neuralink’s first step toward international validation. |
What’s Next?
In the near term, Neuralink seems focused on:
- Expanding participant numbers while continually refining hardware and software usability.
- Ensuring trial safety across different setups and demographics.
- Managing regulatory expansion from the U.S. to international research environments, beginning with the United Kingdom.
Summary
Neuralink has achieved a key milestone by implanting its N1 brain-computer interface in 12 individuals globally, marking substantial progress in its mission to bridge human thought and digital action. With thousands of hours of use logged and plans to begin clinical trials in the UK, Neuralink continues to chart new territory in neurotechnology.
